Combining Diagnostics and Artificial Intelligence enabling Precision Medicine, Risk Prediction and Prognosis to Guide Therapy.
Application of LIVERFASt to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome
Poster presented for SHC July 2024
•To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in detecting hepatic steatosis in chronic hepatitis B
• To correlate LIVERFASt steatosis with Fibroscan Controlled Attenuation Parameter (CAP) scores
Application of lIVERFASt Biomarkers to Evaluate Longitudinal Hepatic Fibrosis and Inflammation after HCV cure
Poster presented for SHC July 2024
• To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in evaluating changes in fibrosis and inflammation post-DAA therapy
• To identify risks associated with HCC and liver disease progression after HCV cure post-DAA
Comparison of the prevalence of advanced fibrosis (AF) using two combinations: Liver stiffness measurement (LSM or VCTE Fibroscan) along with LIVERSTAT (LST) or FIB-4 in a prospective chronic liver diseases (CLD) cohort
Poster presented for SHC July 2024
Comparative assessments of the prevalence of advanced fibrosis (F3F4) using one-step combination LiverSTAT & LSM versus FIB-4 & LSM in a miscella
Comparison of two non-invasive models for the detection of presumed advanced fibrosis (pAF) in patients (pts) with type 2 diabetes (T2D) and MASLD using LIVERSTAT(LSTAT) and FIB-4 in combination with liver stiffness measurement (LSM) by Fibroscan
Poster presented for SHC July 2024
This study aims to retrospectively evaluate two combinations, LIVERSTAT & Liver Stiffness measurement (LSM) and FIB-4 & LSM, in identifying presumed advanced fibrosis among pts with T2D and MASLD.
Combination of LIVERSTAT (LST) and Fibroscan (LSM) Outperforms FIB-4 and LSM for MASLD Advanced Fibrosis (AF) F3F4
Poster presented for ADA June 2024
This study aims to retrospectively compare the efficacy of two combinations in onestep approach : LIVERSTAT & LSM versus FIB-4 & LSM, for the identification of advanced fibrosis (F3F4) in a multicenter multiethnic meta-dataset of MASLD patients.
Association between Psoriasis Severity and Steatosis Measured by Artificial Intelligence-based Algorithm (LIVERFASt)
Poster presented for EASL June 2024
This study aims to explore the association between psoriasis severity and steatosis by utilising a non-invasive test, LIVERFASt.
Association Comparison of two non-invasive models for advanced fibrosis (AF) detection in patients with type 2 diabetes (T2D) and MASLD using LIVERSTAT, FIB-4 and liver stiffness measurement (LSM) with transient elastography (TE)
Poster presented for EASL June 2024
This study evaluated the efficacy of using LST and LSM in identifying advanced fibrosis among patients with T2D and MASLD comparatively to FIB-4 and LSM.
Combination of LIVERFASt (LF) & Liver Stiffness Measurement (LSM) using Fibroscan outperforms FIB-4 & LSM, for the identification of MASLD advanced fibrosis (AF) in patients with type 2 diabetes (T2D
Poster presented for EASL June 2024
The study aims to compare retrospectively two combinations for one-step assessment of advanced fibrosis: LIVERFASt Fibrosis & Liver Stiffness Measurement (LSM, Fibroscan) versus FIB-4 & LSM, for the identification of histological advanced fibrosis in patients with Type 2 diabetes (T2D) that undergone liver biopsy (LB).
Combination of LIVERSTAT and Fibroscan (LSM) Outperforms FIB-4 and LSM, for MASLD Advanced Fibrosis (F3F4)
Poster presented for NASH Tag Jan 2024
The study aims to retrospectively compare, the efficacy of two combinations in one-step approach with two biomarkers, LiverSTAT and LSM versus FIB-4 and LSM for the identification of advanced fibrosis (F3F4) in a multicenter multiethnic dataset of MASLD patients.
LIVERFASt (L-FAST) identifies advanced (F3F4, AF) and clinically significant fibrosis (F2-F4, CSF) especially well with Fibroscan in MASLD patients (pts) from a tertiary hepatology center.
Poster presented for NASH Tag Jan 2024
The study aims to compare retrospectively the performance of one-step strategy with two noninvasive combinations, the standard-of care, FIB-4 & LSM, versus LIVERFASt-Fibrosis & LSM, for the identification of histological AF and CSF in MAFLD pts.
- As defined by Eslam M. et al. (J. Hepatol. 2020, MAFLD: metabolic-associated fatty liver disease
Recommended Clinical Care Pathway (CCP) with FIB-4 Underestimates the prevalence of advanced fibrosis (AF) compared to sequential ccp with LIVERFASt GP+ (LIVERSTAT) and liver stiffness measurement (LSM) by Fibroscan
Poster presented for AASLD Nov 2023
The study aims to assess comparatively, on the 2017 March 2020 pre-pandemic NHANES cohort, the prevalence of advanced fibrosis (AF) using recommended sequential FIB-4 and LSM and using the newly released triage tool, LIVERSTAT, downstream of liver stiffness measurement (LSM) with vibration controlled transient elastography (VCTE) by Fibroscan.
Validation of LIVERSTAT as a non-invasive test for risk stratification for patients with metabolic-dysfunction associated fatty liver disease (MAFLD): a single-centre study using liver biopsy as reference standard
Poster presented for AASLD Nov 2023
The study aimed to validate LIVERSTAT in patients with metabolic dysfunction associated fatty liver disease (MAFLD) and to explore its role in combination with other non-invasive tests for the diagnosis of advanced fibrosis.
Application of LIVERFASt™ to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome
Poster presented for AASLD Nov 2023
The study aims:
• To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in detecting hepatic steatosis in chronic hepatitis B
• To correlate LIVERFASt steatosis with Fibroscan Controlled Attenuation Parameter (CAP) scores
A Public Health Initiative from the American Liver Foundation Demonstrates the Feasibility of a Screening Program for Metabolic Dysfunction-Associated Steatotic Liver Disease
Poster presented for AASLD Nov 2023
The goal was to provide a “first screen” program in federally-qualified health centers and community clinics serving populations at high-risk for MASLD, followed by education and connection to care. Additionally, another objective of our pilot program was to demonstrate the feasibility and need for widespread screening of MASLD in the primary care setting.
Application of LIVERFASt biomarkers to evaluate longitudinal hepatic fibrosis and inflammation after HCV cure
Poster presented for AASLD Nov 2023
The primary aim was
- To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in evaluating changes in fibrosis and inflammation post-DAA therapy
- To identify risks associated with HCC and liver disease progression after HCV cure post-DAA
LIVERFASt GP+ (LIVERSTAT), first-line screening tool in at-risk MAFLD patients outperformed standard of-care (SOC) FIB-4
Poster presented for EASL June 2023
The primary aim was to construct and validate a new MAFLD screening test, GP+, noninferior to the SOC reference, FIB-4, for advanced fibrosis (F3F4 stages), and with less drawbacks related to age cutoffs.
LIVERFASt GP+(LIVERSTAT), a non-invasive blood testing for NAFLD staging improves risk stratification of patients with indeterminate FIB-4 results
Poster presented for EASL June 2023
The primary aim was to assess retrospectively the GP+ (LIVERSTAT) performance and concordance rate (CR) with liver biopsy and Fibroscan as second step after FIB-4 for the assessment of advanced fibrosis (F3F4) in NAFLD patients.
Comparative assessment of noninvasive methods (NIMS) – LIVERFASt™, liver stiffness measurement (LSM) with transient elastography (TE, Fibroscan), ELF and Fib-4 – in a prospective cohort with chronic liver diseases (CLD) from a tertiary liver center
Poster Presented June 2022
In a prospective tertiary cohort with CLD, to assess clinical performance against liver biopsy of different NIMs :
- For advanced and bridging fibrosis: LIVERFASt Fibrosis test, Enhanced liver fibrosis score (ELF), FIB-4 and LSM using vibration controlled transient elastography (VCTE).
- For steatosis (mild, moderate and marked): LIVERFASt Steatosis test and CAP (Fibroscan) in NAFLD patients, including a control group with CLD without steatosis (S0)].
Repeated noninvasive liver biopsy surrogate LIVERFASt™ correlates with BMI and liver enzymes improvements
Poster Presented June 2022
To assess liver fibrosis regression rate (LFR) USING repeated LIVERFASt AND CORRELATIONS with IMPROVEMENTS IN clinical endpoints, body mass index BMI ≥ 10% and liver enzymes ALT ≥ 50%from baseline.
Noninvasive LIVERFASt™ transition rate to liver fibrosis is similar to that estimated with liver biopsy in NAFLD patients
Poster Presented June 2021
To demonstrate that LIVERFASt™ Fibrosis score (LF-Fib) is a surrogate of liver biopsy (LB) for the estimation of the transition rate to fibrosis F1 stage or more (TRF1), in type 2 diabetic (T2D) patients with better performances than liver stiffness measurement (LSM) by transient elastography and than FIB-4 index.
Long-term prognosis of MAFLD patients according to noninvasive methods
Poster Presented Nov 2021
To assess the prognostic value of noninvasive methods in MAFLD patients.
Simulating clinical confidence intervals for black-box algorithmic predictions of liver steatosis.
Poster Presented September 2020
Clinicians have begun using blood-serum biomarkers with artificial intelligence algorithms (AIAs) to assess the degree of liver steatosis without taking a liver biopsy. However, intra-patient and intra-lab variability could affect the inputs, and with >5 biomarkers used by an AIA, noise is compounded. Interpretable measures of an AIA’s confidence are absent in the clinical workflow. We aim to resolve this gap in interpretability of non-invasive AIA with a stochastic noise injection method and interactive data visualization—allowing clinicians to a) observe steatosis predictions under simulated noise conditions and b) interactively simulate expected regression of steatosis with respect to changes in biomarkers through course of treatment.
Comparative assessment liver lesions using non-invasive serum biomarkers LIVERFASt™, FIB4, APRI and liver stiffness measurement (LSM, FibroScan) in chronic hepatitis C(CHC) patients with liver biopsy.
Poster Presented September 2020
Despite the high efficacy of current direct acting agents (DAA), in Thailand CHC is still a leading cause of liver-related morbidity and mortality and staging of liver fibrosis is critical for the management of outcomes in patients even after viral cure. LIVERFAStTM (LF, Fibronostics, US) is a proprietary technology based in serum biomarkers to assess quantitatively liver fibrosis (LF-Fib), necroinflammatory (NAI) activity (LF-Act) and steatosis (LF-Ste).
Predictive Value of Non-Invasive Methods LIVERFASt™, Acoustic Radiation Force Impulse (ARFI), FIB-4 and APRI to Identify the Natural Phases of Chronic Hepatitis B (CHB) Infection from the National University Hospital (NUH) CHB Study Cohort of Singapore
Poster Presented September 2020
In order to determine the outcomes and progression to significant liver fibrosis (SLF) as per ARFI, we set up a prospective NUH HBV cohort with chronic HBV infection (Ch.Inf) expected to have no/minimal liver disease vs moderate/severe in chronic hepatitis (Ch.Hep) patients (pts).(JHepatol2017) LIVERFASt (LF, Fibronostics, US), is a patented technology to assess liver fibrosis(LF-F) and activity(LF-A).
Evaluating serum biomarkers LIVERFASt™ surrogates of liver fibrosis and steatosis could identify risks in a clinical population experiencing SARS-COV2 infection (COVID 19).
Paper Presented September 2020
Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Age, diabetes and metabolic factors has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of patients (pts) in COVID-19 are unknown. For clinicians, it’s imperative to predict the outcome of a given patient following a positive test for SARS-CoV2—it is known that prior health history and demographics are informative towards describing the wide range of prognostic outcomes for COVID19 pts.
Comparative Performances of LIVERFASt™, VTCE (Fibroscan) and other serum non-invasive tests (NITs) for the diagnosis of advanced chronic liver disease in non-alcoholic fatty liver disease (NAFLD) patients from a cohort with liver biopsy.
Poster Presented September 2020
There is a call for action in the management of patients with type 2 diabetes mellitus (T2DM) and steatohepatitis (NASH) LIVERFASt (LF) is a serum-based proprietary panel for assessing fibrosis (LF-Fib), steatosis (LF-Ste) and activity (LF-Act) in NAFLD patients.
Poster Presented June 2020
According to the American Society for Metabolic and Bariatric Surgery (ASMBS)1, non-alcoholic fatty liver disease (NAFLD) is one of the obesity-related co-morbidities that qualifies a patient to undergo a bariatric surgery if BMI> 35. By 2030, it is predicted that nearly half of adults in the USA will have obesity2. Over 80% of the patients with obesity submitted to bariatric surgery suffer from (NAFLD), with 25% – 55% resulting in steatohepatitis (NASH) and 2% – 12% liver fibrosis and cirrhosis3.
Poster Presented May 2020
Dr. Sam Pappas uses the capabilities of Artificial Intelligence (AI) algorithm LIVERFASt blood-based test for evaluation of liver disease, fatty liver disease and NASH (Non-Alcoholic Steatohepatitis) to provide excellent care for his patients.
Machine Learning Technology for Evaluation of Liver Fibrosis, Inflammation Activity and Steatosis (LIVERFASt™)
Poster Presented April 2020
Use of non-invasive liver tests in extended populations is evaluated in 13068 patients who underwent the LIVERFASt test for fatty liver disease assessment. Data evaluation revealed 11% of the patients exhibited significant fibrosis, approximately 7% of the population had severe hepatic inflammation, and steatosis was observed in most patients, 63%, whereas severe steatosis S3 was observed in 20%. Using modified SAF (Steatosis, Activity and Fibrosis) scores obtained using the LIVERFASt algorithm, NAFLD was detected in 13.41% of the patients.
Poster Presented January 2020
Scientific poster presented at the NASH-TAG conference, January 2020 for “Assessment of fatty liver disease using a biomarker-based non-invasive algorithm LIVERFASt test in South-East Asia”.
At NASH-TAG international conference, clinicians and researchers share the latest advances and challenges in the diagnosis and therapy of NASH and liver fibrosis.
Non-Invasive Assessment Of Liver Fibrosis, Inflammation And Steatosis
Poster Presented November 2019
The LIVERFASt machine learning-based algorithm uses a combination of anthropometric and serum biomarkers that are individually used to provide fatty liver disease staging. It is a reliable, and reproducible tool which provides grading or staging of the three liver lesions: fibrosis, inflammation activity and steatosis.
Non-invasive testing for fatty liver disease for primary care providers
Poster Presented November 2018
High sensitivity and specificity indicating “Elevated” or “Low” risk for NAFLD can be achieved using a simple algorithm based on minimal information from patients seeking routine check-ups from Primary Care Physicians or PCPs. The algorithmic result is significantly more precise than current reliance on identification of outlier values for standard individual liver function biomarkers. Furthermore, most patients at elevated risk can be evaluated for quantitative SAF score prediction using additional biomarkers – without undergoing expensive or invasive procedures of elastography, imaging or biopsy.